Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05655546 · ClinicalTrials.gov registry record · NA
ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
A NA study, sponsored by Scripps Translational Science Institute.
- Terminated
- Registry status
- NA
- Development phase
- 2,117
- Enrollment target
NCT05655546 is a NA study that was terminated before completion, run by Scripps Translational Science Institute. The registered enrollment target is 2,117 participants.
The verdict
NCT05655546, a NA study, was terminated before completion, sponsored by Scripps Translational Science Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 2,117 participants
- Enrollment target
Study Summary
The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those who are 65 years and older. They will also analyze whether these efforts lower the cost of care compared to standard of care.
Interventions
- OTHER Access to Cue Health COVID-19 Remote testing and treatment for COVID-19
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,117 participants |
| Start Date | 2022-12-22 |
| Est. Completion | 2024-06-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05655546
The ClinicalTrials.gov registry entry for NCT05655546 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 2,117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Translational Science Institute, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 is the first listed.
NCT05655546 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05655546 about?
NCT05655546 is a clinical study titled "ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals". The investigators will examine whether a combination of at-home nucleic acid amplification tests, on-demand telemedicine, and delivery of prescriptions such as Paxlovid quickly after testing positive for COVID-19, can reduce severe outcomes and hospitalization of immunocompromised patients and those...
What is the current status of trial NCT05655546?
This trial is currently terminated. It is a NA study. The enrollment target is 2,117 participants. The study started on 2022-12-22. Estimated completion is 2024-06-20.
What interventions are being tested in trial NCT05655546?
The interventions under investigation include: Access to Cue Health COVID-19 Remote testing and treatment for COVID-19 (OTHER).
Who is sponsoring clinical trial NCT05655546?
This trial is sponsored by Scripps Translational Science Institute, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.